Bendamustine (Treanda) for CLL and NHL

Medical Letter on Drugs and Therapeutics

Volumn 50, Issue 1299, 2008, Pages 91-92

  Abramowicz, Mark ⁿ   Zuccotti, Gianna ^a   Pflomm, Jean Marie ⁿ   Daron, Susan M ⁿ   Houst, Blaine M ⁿ   Zanone, Corinne E ⁿ   Dalton, Vanessa K ^b   Epstein, Eric J ^c   Hirsch, Jules ^d   Juurlink, David N ^e   Kim, Richard B ^f   Mandell, Gerald L ^g   Meinertz, Hans ^h   Roden, Dan M ⁱ   Simons, F Estelle R ^j   Steigbigel, Neal H ^k   Goodstein, Donna ⁿ   Faucard, Amy ⁿ   Covey, Cynthia Macapagal ⁿ   Schwartz, Lauren K ^l   Cassagnol, Manouchkathe ^m   Brown, Cheryl ⁿ   Donohue, Liz ⁿ   Wong, Susie ⁿ   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF VIRGINIA   (United States)

^h Mental Health Center Glostrup   (Denmark)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MANITOBA   (Canada)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m ST JOHN'S UNIVERSITY   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CARBAMAZEPINE; CHLORAMBUCIL; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; FLUVOXAMINE; FLUVOXAMINE MALEATE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DEATH; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EUROPE; FATIGUE; FEVER; HUMAN; HYPOTENSION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; RIGOR; SHORT SURVEY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UNITED STATES; ARTICLE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; NITROGEN MUSTARD COMPOUNDS;

EID: 70349904594     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. LM Leoni et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008: 14:309.
2. JW Friedberg et al. Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkins's lymphoma: Results from a phase II multicenter single-agent study. J Clin Oncol 2008; 26:204.
3. WU Knauf et al. Bendamustine versus chlorambucil in treatment- naïve patients with B-cell chronic lymphocytic leukemia (CCL) results of an international phase III study. Blood 2007; 110:abstract 2043.
4. KR Rai et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750.
5. JC Byrd et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALG 9011. Blood 2005; 105:49.
6. MJ Keating et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23:4079.
7. K Fischer et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG). Blood 2007; 110, abstract 3106.
8. B Kahl et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Blood 2007; 110: abstract 1351.
9. KS Robinson et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: a phase II multicenter study. J Clin Oncol 2008; 26:4473.